These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 11668426)

  • 41. Latest medical treatment strategies for venous thromboembolism.
    McRae SJ; Eikelboom JW
    Expert Opin Pharmacother; 2007 Jun; 8(9):1221-33. PubMed ID: 17563258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hirudin, a new therapeutic tool?
    Bichler J; Fritz H
    Ann Hematol; 1991 Aug; 63(2):67-76. PubMed ID: 1912033
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost reduction associated with heparin-induced thrombocytopenia panel ordering for enoxaparin versus heparin for prophylactic and therapeutic use: A retrospective analysis in a community hospital setting.
    Menon H; Pillai A; Aussenberg-Rodriguez J; Ambrose J; Youssef I; Griffiths EA; Al Ustwani O
    Avicenna J Med; 2018; 8(4):133-138. PubMed ID: 30319954
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The potential role of new therapies in deep-vein thrombosis prophylaxis.
    Wille-Jørgensen P
    Semin Hematol; 2001 Apr; 38(2 Suppl 5):20-30. PubMed ID: 11449340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outpatient management of venous thromboembolic disease with subcutaneous lepirudin: a case report.
    Begelman SM; Deitcher SR
    J Thromb Thrombolysis; 2002 Jun; 13(3):183-5. PubMed ID: 12355036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of experimental venous thrombosis in rabbits with different low molecular weight heparins, dermatan sulphate and hirudin.
    Matthiasson SE; Lindblad B; Bergqvist D
    Haemostasis; 1995; 25(3):124-32. PubMed ID: 7607580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Looking forward in the treatment of deep-vein thrombosis.
    Turpie AG
    Semin Hematol; 2001 Apr; 38(2 Suppl 5):49-57. PubMed ID: 11449343
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Future directions in antithrombotic therapy: emphasis on venous thromboembolism.
    Axelrod DA; Wakefield TW
    J Am Coll Surg; 2001 May; 192(5):641-51. PubMed ID: 11333101
    [No Abstract]   [Full Text] [Related]  

  • 49. Recombinant hirudins: an overview of recent developments.
    Zeymer U
    BioDrugs; 1998 Dec; 10(6):425-36. PubMed ID: 18020612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low molecular weight heparins.
    Bergqvist D
    J Intern Med; 1996 Aug; 240(2):63-72. PubMed ID: 8810931
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hirudin treatment in a breastfeeding woman.
    Lindhoff-Last E; Willeke A; Thalhammer C; Nowak G; Bauersachs R
    Lancet; 2000 Feb; 355(9202):467-8. PubMed ID: 10841132
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism.
    Heit JA
    Chest; 2003 Sep; 124(3 Suppl):40S-8S. PubMed ID: 12970123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk assessment of venous thromboembolism in medical patients.
    Harenberg J
    Semin Hematol; 2000 Jul; 37(3 Suppl 5):3-6. PubMed ID: 11055888
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Heparin in interventional radiology: a therapy in evolution.
    Resnick SB; Resnick SH; Weintraub JL; Kothary N
    Semin Intervent Radiol; 2005 Jun; 22(2):95-107. PubMed ID: 21326679
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antithrombotic therapy and cancer.
    Di Nisio M; Squizzato A; Klerk CP; Richel DJ; Büller HR
    Curr Opin Hematol; 2004 May; 11(3):187-91. PubMed ID: 15257019
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of venous thromboembolism in acute medical illness.
    Enders JM; Burke JM; Dobesh PP
    Pharmacotherapy; 2002 Dec; 22(12):1564-78. PubMed ID: 12495167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lepirudin: a review of its potential place in the management of thrombotic disorders.
    Adkins JC; Wilde MI
    BioDrugs; 1998 Sep; 10(3):227-55. PubMed ID: 18020598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Role of Antithrombin Agents and Factor Xa-Inhibitors in Antithrombotic Treatment.
    Breddin HK
    Turk J Haematol; 2002 Jun; 19(2):113-20. PubMed ID: 27264751
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment and secondary prophylaxis of VTE in the cancer patient: current status.
    Lee AY
    Pathophysiol Haemost Thromb; 2003; 33 Suppl 1():42-3. PubMed ID: 12955000
    [No Abstract]   [Full Text] [Related]  

  • 60. Hirudin CGP 39393 as thromboprophylaxis.
    Williams DJ; Mahomed A
    Lancet; 1996 Jun; 347(9014):1561-2. PubMed ID: 8684139
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.